Specialty Pharmaceuticals for Hyperlipidemia — Impact on Insurance Premiums  

Oleh:

Schulman, Kevin A. ; Balu, Suresh ; Reed, Shelby D.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 373 no. 17 (Oct. 2015), page 1591-1593.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

The Food and Drug Administration (FDA) recently approved alirocumab and evolocumab, PCSK9 inhibitors, for the treatment of hyperlipidemia. These novel biologic agents offer the promise of reductions in blood cholesterol levels. Specifically, the FDA approved alirocumab as an “adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL [low-density lipoprotein]-cholesterol.”1 This broad indication sets the practice of cardiology on a collision course with specialty pharmaceutical pricing models that were previously reserved for drugs that benefited relatively limited patient populations.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali